Intas Enters into an Exclusive License Agreement with Meiji and Dong-A ST to commercialize DMB-3115 (Proposed Biosimilar to Ustekinumab)

Intas Pharmaceuticals Ltd

2021/7/22 19:59

PR90785

 

AHMEDABAD, India, July 22, 2021 /PRNewswire=KYODO JBN/ --

 

Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing

access to high quality medicines by entering into an exclusive license

agreement

 

Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing

access to high quality medicines by entering into an exclusive license

agreement with Meiji and Dong-A Socio Holdings (a parent company of Dong-A ST)

to commercialize DMB-3115, a proposed biosimilar to ustekinumab, a recombinant

monoclonal antibody for the treatment of autoimmune and inflammatory diseases

such as plaque psoriasis, Crohn's disease and ulcerative colitis.

 

Under the terms of the agreement, Intas have been granted exclusive license

rights to commercialize DMB-3115 worldwide, excluding Japan, Korea and certain

countries in Asia. Meiji and Dong-A ST will develop and manufacture DMB-3115

and supply the product to Intas and its worldwide affiliates.

 

This is yet another industry first for Intas, one of the leaders in the

development and commercialization of biosimilar products, who are the first

Indian company to launch a biosimilar product in the EU.

 

"We are truly excited by this partnership, which brings together the

development expertise of Meiji and Dong-A ST with the extensive commercial

reach of Intas," said Vice Chairman, Mr. Binish Chudgar. "This agreement

underlines our vision and commitment to increase access to life-changing

medicines that can make a real difference to patient lives across the world,"

said Chrys Kokino, President of Accord BioPharma, Inc., the US specialty

subsidiary of Intas.

 

About Dong-A ST

 

Dong-A is one of the leading pharmaceuticals in Korea. Dong-A has solidified

its leading market position on the strength of in-house developed products such

as Suganon tab. Evogliptin, the DPP-4 inhibitor for type 2 diabetes mellitus,

Zydena tab. Udenafil, the fourth PDE5 inhibitor in the world for erectile

dysfunction, Stillen tab. Eupatilin for herbal treatment of gastritis and

Motilitone tab. Corydaline for functional dyspepsia. Furthermore, Dong-A offers

branded generic drugs (anti-cancer, anti-TB, etc.), bio-pharmaceutical, IMD,

APIs and OTC products ensuring full compliance with international quality

standard. Currently Dong-A exports its products to more than 50 countries to

leading pharmaceutical companies in Europe, Latin America and Asia.

 

For more information, please visit http://en.donga-st.com.

 

About Meiji

 

Meiji is a leading pharmaceutical company in Japan in the therapeutic areas of

infectious diseases and central nervous system disorders. Since entering pharma

industry with launch of penicillin in 1946, Meiji has been accumulating

proprietary technologies on R&D and manufacture of small molecules as well as

biotherapeutics and is providing high-quality pharmaceutical products to

customers in Japan and overseas. Meiji continues to accommodate customer's

diverse medical requirements as a "Specialty and Generic Pharmaceuticals

Company".

 

For more information, please visit

 

https://www.meiji.com/global/about-us/corporate-profile/meiji-seika-pharma/

 

About Intas

 

Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical

company based in Ahmedabad, India, having end-to-end capabilities of

formulation development, manufacturing and marketing along with backward

integration of APIs. Intas has more than 16,000 employees, sells products in

more than 85 countries and has 14 manufacturing sites worldwide. The Intas

group's revenues amounted to USD 2.1 bn in FY 2020 and the compounded annual

growth rate of Intas' revenues has exceeded 25% in the past 10 years.

 

For more information, please visit www.intaspharma.com

 

 

Source: Intas Pharmaceuticals Ltd

 

 

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中